Daiichi Sankyo Co., Ltd. (DSKYF)
14.86
-1.34
(-8.27%)
USD |
OTCM |
Jun 09, 16:00
Daiichi Sankyo Enterprise Value : 26.10B for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 26.10B |
| June 08, 2026 | 28.54B |
| June 05, 2026 | 26.87B |
| June 04, 2026 | 26.46B |
| June 03, 2026 | 29.92B |
| June 02, 2026 | 28.90B |
| June 01, 2026 | 30.09B |
| May 29, 2026 | 30.22B |
| May 28, 2026 | 30.22B |
| May 27, 2026 | 29.36B |
| May 26, 2026 | 31.31B |
| May 22, 2026 | 29.03B |
| May 21, 2026 | 30.86B |
| May 20, 2026 | 28.47B |
| May 19, 2026 | 28.18B |
| May 18, 2026 | 28.18B |
| May 15, 2026 | 30.05B |
| May 14, 2026 | 30.72B |
| May 13, 2026 | 29.36B |
| May 12, 2026 | 30.53B |
| May 11, 2026 | 30.36B |
| May 08, 2026 | 30.17B |
| May 07, 2026 | 30.17B |
| May 06, 2026 | 29.50B |
| May 05, 2026 | 29.63B |
| Date | Value |
|---|---|
| May 04, 2026 | 29.54B |
| May 01, 2026 | 28.16B |
| April 30, 2026 | 27.72B |
| April 29, 2026 | 29.29B |
| April 28, 2026 | 28.25B |
| April 27, 2026 | 29.05B |
| April 24, 2026 | 28.51B |
| April 23, 2026 | 30.83B |
| April 22, 2026 | 31.91B |
| April 21, 2026 | 31.91B |
| April 20, 2026 | 31.36B |
| April 17, 2026 | 33.35B |
| April 16, 2026 | 30.72B |
| April 15, 2026 | 32.18B |
| April 14, 2026 | 30.74B |
| April 13, 2026 | 30.64B |
| April 10, 2026 | 30.74B |
| April 09, 2026 | 31.41B |
| April 08, 2026 | 31.41B |
| April 07, 2026 | 32.13B |
| April 06, 2026 | 31.86B |
| April 02, 2026 | 32.40B |
| April 01, 2026 | 32.39B |
| March 31, 2026 | 32.57B |
| March 30, 2026 | 32.24B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Astellas Pharma, Inc. | 25.60B |
| Takeda Pharmaceutical Co., Ltd. | 76.62B |
| Eisai Co., Ltd. | 6.293B |
| Chugai Pharmaceutical Co., Ltd. | 69.78B |
| Santen Pharmaceutical Co., Ltd. | 3.421B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 270.42M |
| Revenue (Quarterly) | 3.758B |
| Total Expenses (Quarterly) | 3.487B |
| EPS Diluted (Quarterly) | 0.1472 |
| Gross Profit Margin (Quarterly) | 48.70% |
| Profit Margin (Quarterly) | 7.20% |
| Earnings Yield | 6.29% |
| Operating Earnings Yield | 5.07% |